Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To test pharmacodynamic response to clopidogrel 150mg once daily during 7 days in healthy subjects carriers of a mutated allele (*2) associated with CYP2C19 deficiency and non responders to the usual regimen of 75 mg once daily
Condition or disease
Thirty individuals genotyped for specific variants of 2C19 cytochrome and P2Y12 platelet ADP receptor will receive during one week a daily dose of 75 mg of clopidogrel. Depending on their pharmacodynamic response to this dose of clopidogrel, subjects will be affiliated to two groups, "good responders" and "bad responders". After a wash-out period, "bad responders" will receive a double dose of clopidogrel, while the "good responders" will receive 75 mg of clopidogrel, associated with a CYP2C19 inhibitor. Such study will allow to evaluate both the impact of raising daily dose of clopidogrel in patients with defected variants of 2C19 and potential interactions of clopidogrel with other drugs.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 35 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy volunteers, aged 18 to 35, non smoker, of caucasian origin
Compatible 2C19 and P2Y12 genotypes
Weight 60 kg to 100 kg, and normal BMI
Standard laboratory investigations normal
Negative testing for HIV infection and B and C hepatitis
Basal platelet agregation testing normal
EKG, blood pressure and cardiac frequency in normal range
Ability to understand, follow and sign the protocol
Evolutive medical affection, even treated
Medical history of allergic response to medication or other, peptic ulcer, or known hemorrhagic disorder